IP Library Granted Patent US 12,351,623
Granted Patent B2
US 12,351,623 · App. 17/511,230 · Granted Jul 8, 2025

Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates

Inventors: Omar El-Agnaf (Doha, QA); Nour Khaled Majbour (Doha, QA); Nishant Vaikath (Doha, QA)
Assignee: HAMAD BIN KHALIFA UNIVERSITY
C07K16/18C12N5/163G01N33/6896C07K2317/14C07K2317/34C07K2317/565C07K2317/76G01N2800/2835
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,623
App. No.
17/511,230
Granted
Jul 8, 2025
Kind
B2
Abstract

The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

Claims (6)

1. A monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

i. the VH comprises heavy chain complementarity determining regions (HCDRs) 1-3 having the amino acid sequences of SEQ ID NOs:7-9, respectively; and

ii. the VL comprises light chain complementarity determining regions (LCDRs) 1-3 having the amino acid sequences of SEQ ID NOs:13-15, respectively.

2. The monoclonal antibody of claim 1 , wherein the antibody is an intact antibody.

3. The monoclonal antibody of claim 1 , wherein VH comprises the amino acid sequence of SEQ ID NO:6 and VL comprises the amino acid sequence of SEQ ID NO:12.

4. The monoclonal antibody of claim 3 , wherein the antibody is an intact antibody.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2025
From: QATAR FOUNDATION FOR EDUCATION, SCIENCE & COMMUNITY DEVELOPMENT
To: HAMAD BIN KHALIFA UNIVERSITY
Reel/Frame 069936/0656 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: EL-AGNAF, OMAR; MAJBOUR, NOUR KHALED; VAIKATH, NISHANT
To: QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT
Reel/Frame 058844/0057 →
Continuity (3)
Continuation In Part PCTQA2021050019 · Sep 17, 2021
Provisional Application 63079767 · Sep 17, 2020
Related Publication 20220089708A1 · Mar 24, 2022
References Cited (13)
US 8092801B2 · Schenk et al. · 2012 [cited by applicant]
US 8613905B2 · El-Agnaf · 2013 [cited by applicant]
US 8632776B2 · Nordstrom et al. · 2014 [cited by applicant]
US 8778334B2 · El-Agnaf et al. · 2014 [cited by applicant]
US 8795664B2 · Bayer · 2014 [cited by examiner]
US 9534044B2 · El-Agnaf · 2017 [cited by applicant]
US 10208111B2 · El-Agnaf · 2019 [cited by applicant]
US 10464999B2 · Liu · 2019 [cited by examiner]
US 10488417B2 · El-Agnaf · 2019 [cited by applicant]
US 10548984B2 · El-Agnaf · 2020 [cited by applicant]
US 11155608B2 · Luk · 2021 [cited by examiner]
WO WO2005047860A2 · 2005 [cited by examiner]
Preliminary Report on Patentability for related International Application No. PCT/QA2021/050019 action dated Mar. 21, 2023; (8 pages). [cited by applicant]